Abcl stock forecast.

13 sept 2023 ... ABCL stock has a median price target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00, indicating potential for substantial ...

Abcl stock forecast. Things To Know About Abcl stock forecast.

Symbol Lookup from Yahoo Finance. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Apple Inc. Common Stock. $191.45 +1.76 +0.93%. Find the latest dividend history for AbCellera Biologics Inc. Common Shares (ABCL) at Nasdaq.com.AbCellera Biologics Inc stock price forecast for further price development down to -37.16% (time horizon: 1 day) and price target of 4.13 USD. Short-term (time horizon: 2 weeks) AbCellera Biologics Inc share price prediction for 2024-01-05 with daily closed price projectionsAccording to the issued ratings of 4 analysts in the last year, the consensus rating for Coupang stock is Moderate Buy based on the current 2 hold ratings and 2 buy ratings for CPNG. The average twelve-month price prediction for Coupang is $22.50 with a high price target of $25.00 and a low price target of $20.00.

Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business.

Long-term ABCL price forecast for 2025, 2030, 2035, 2040, 2045 and 2050. Our analysts are offering long term price forecasts for AbCellera Biologics Inc In 2050, the median target price for ABCL is $317.20, with a high estimate of $352.81 and a low estimate of $30.87. The median estimate represents a +6,902% increase from the last price of $4. ...Shares of AmerisourceBergen Corp. ABC, slumped 0.33% to $166.85 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, -0.09% rising ...

Stock Price Forecast. According to 14 stock analysts, the average 12-month stock price forecast for Palantir stock is $13.25, which predicts a decrease of -34.63%. The lowest target is $5.00 and the highest is $25. On average, analysts rate …Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 27, 2023 · AbCellera Biologics (ABCL) is a biotech company that discovers antibodies from natural immune responses. The company has a consensus rating of Buy and a forecasted upside of 461.1% from its current price of $4.04. See the latest news, analysis, earnings, and insider trading of ABCL stock on MarketBeat. Nov 29, 2023 · Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low. Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …

Being prepared to weather a hurricane — whether that involves fortifying your home or creating an emergency evacuation plan — is an important part of making it through the storm. Hurricanes travel across the ocean via massive, circular gust...

Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business.

Great weather can motivate you to get out of the house, while inclement weather can make you feel lethargic. When the weather’s great we want to be outside enjoying it. For the best regional weather forecasts check out AccuWeather.Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more ...According to our research, ABCL stock is a bad long-term investment. ABCL share price has been in a bear cycle for the past year. AbCellera Biologics Inc. …Nov 13, 2023 · High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years. Revenue vs Market: ABCL's revenue (23.9% per year) is forecast to grow faster than the US market (8% per year). High Growth Revenue: ABCL's revenue (23.9% per year) is forecast to grow faster than 20% per year. Australian property values are expected to stabilise as more homes come up for sale and buyers remain wary of high borrowing costs. Here's how your capital city fared …Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts ABCL's market cap stands at $2.07B, with total debt ...

Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of AbCellera Biologics The definition of company insiders can be subjective and does ...ABCL: AbCellera Biologics - Price and Consensus Chart. Get the latest Price and Consensus Chart for AbCellera Biologics from Zacks Investment ResearchDec 31, 2020 · ABCL's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks). ABCL Stock Summary. The price/operating cash flow metric for ABCELLERA BIOLOGICS INC is higher than 98.57% of stocks in our set with a positive cash flow. ABCL's price/sales ratio is 23.26; that's higher than the P/S ratio of 95.29% of US stocks. ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ...Nov 2, 2023 · AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.

"ABCL" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "ABCL" projections. At Walletinvestor.com we …

Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Microbot Medical Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median ...Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Apple Inc. Common Stock. $191.45 +1.76 +0.93%. Find the latest dividend history for AbCellera Biologics Inc. Common Shares (ABCL) at Nasdaq.com.Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.Analyst Forecast. According to 7 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $22.33, which is an …Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...The average Palantir stock price prediction forecasts a potential downside of 27.3% from the current PLTR share price of $19.20. What is PLTR's forecast return on ...

ABCL stock's Price/Earning ratio is 12.33. Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABCL may be a overvalued for its sector.

Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comABCL | Complete AbCellera Biologics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.ABCL: AbCellera Biologics - Price and Consensus Chart. Get the latest Price and Consensus Chart for AbCellera Biologics from Zacks Investment ResearchAbCellera Biologics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 27,470,000 shares, a drop of 1.2% from the previous total of 27,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting ...After dumping hundreds of millimetres of rain across New South Wales and Queensland, severe storms have moved south, where they are forecast to bring up to …Nov 21, 2023 · According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecasts Business Finance Consider company ABC. Today it is 1st of January 2023 and ABC has just paid a dividend of £3 million. The expected earnings of ABC for the next 30 years are forecast to grow at a rate of 15% per annum. From 1st of January 2053 and onwards the earnings of ABC are expected to grow at a rate of 5%.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Microbot Medical Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median ...Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business.

According to our research, ABCL stock is a bad long-term investment. ABCL share price has been in a bear cycle for the past year. AbCellera Biologics Inc. …12/02/2023. Palantir stock price stood at $20.27. According to the latest long-term forecast, Palantir price will hit $25 by the end of 2023 and then $30 by the middle of 2025. Palantir will rise to $45 within the year of 2026, $55 in 2027, $60 in 2028, $65 in 2029, $70 in 2030, $75 in 2032, $80 in 2033, $85 in 2034 and $90 in 2035.Jul 19, 2023 · Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts ABCL's market cap stands at $2.07B, with total debt ... Instagram:https://instagram. best stock option advisory servicestockwits apple1804 silver dollar coincommercial metal According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.The average Palantir stock price prediction forecasts a potential downside of 27.3% from the current PLTR share price of $19.20. What is PLTR's forecast return on ... 2 year bond rateshow to trade indian stocks from us TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only. sneaker stock https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners.May 4, 2023 · AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.